What You Should Know:
– FriskaAi, an AI-powered healthcare platform, has announced an agreement with Dexcom, Inc., a global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into its platform.
– The collaboration will enable FriskaAi to use continuous glucose data to support physicians and patients with actionable, personalized care management programs.
Physician-Directed Platform for Chronic Disease Management
FriskaAi is a physician-directed health and wellness platform that helps providers take an evidence-based approach to preventive care for diabetes and other chronic diseases. The platform is EHR-agnostic and uses advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health in partnership with their clinical team.
The integration with Dexcom CGMs is a major step in this effort. Dexcom CGMs use a small, wearable sensor to continuously measure and wirelessly send glucose levels to a smart device in real-time, eliminating the need for fingerpricks. The devices also provide customizable alerts for high or low glucose levels and predictive alerts to help users stay within a healthy range.
Integration with Smart Devices and Health Apps
The FriskaAi mobile app securely integrates with Dexcom CGMs and other smart devices and health apps. The data from these devices, along with other clinical information, is continuously monitored by HIPAA-compliant, AI-powered algorithms. These algorithms alert patients when action is recommended and generate actionable reports for clinicians to use at the point of care.
Aggregated health data within the FriskaAi platform is also analyzed to help physicians identify trends and risks within their patient populations, which enables more proactive and preventive care strategies. This partnership is set to enhance chronic disease management by providing timely, personalized insights and empowering both patients and their clinical teams.
“Impacting more than 38 million Americans, diabetes has emerged as a major public health problem, and its effective management has become a foundational element of preventive medicine,” says Shaji Nair, CEO of FriskaAi. “Dexcom’s pioneering CGMs are vital tools not only for diabetes management but also for informing broader care decisions. FriskaAi is excited about the potential this integration with Dexcom presents to the physicians relying on our platform for chronic disease management and the patients seeking greater control over their health and wellness.”
